Micro-RNA 132 and 212 mediated regulation of fatty acid metabolism and its effect on insulin secretion. Prelim Mock Talk by -Mufaddal S Soni Attie Lab.

Slides:



Advertisements
Similar presentations
Control of Gene Expression
Advertisements

CHAPTER 16 Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display.
Pancreatic Islets within Pancreas. Modulators of Insulin Secretion.
3B1 Gene regulation results in differential GENE EXPRESSION, LEADING TO CELL SPECIALIZATION.
THE KETONE BODIES: FROM PROVIDERS OF ENERGY FOR LIFE TO FATAL KILLERS By Prof Morsi Arab University of Alexandria, Egypt.
Gluconeogenesis and Beta- oxiation Lecture 22. Glucogneogenesis Essentially a reversal of glycolysis Pyruvate  Glucose Requires three irreversible steps.
Chapter 9. Regulation of Metabolism Regulation of metabolisms can be at different levels: Systemic level: neuro-hormone regulation Cell level: induction.
BC21D: Bioenergetics & Metabolism The formation of Acetyl Coenzyme A; Krebs cycle; electron transport chains and chemiosmotic phosphorylation mechanism:
Glycolysis Regualtion
Palmitic acid acutely stimulates glucose uptake via activation of Akt and ERK1/2 in skeletal muscle cells Jing Pu, Gong Peng, Linghai Li, Huimin Na, Yanbo.
Metabolic Syndrome: Focused on AMPK as Molecular Target for Metabolic Syndrome Bayu Lestari.
Fig. 1. GLP-1 induces miR-132 and miR-212 expression in pancreatic β-cells in vitro and in vivo. (A) MiRNA expression profiling of GLP-1 treated INS-1.
Micro-RNAs, Fatty Acids and Insulin Secretion Prelim Mock Talk by -Mufaddal S Soni Attie Lab.
Micro-RNAs, Fatty Acids and Insulin Secretion Midwest Islet Conference -Mufaddal S Soni Attie Lab.
Regulation of miRNA 132 and miRNA 212 expresion. Clearly they are up-regulated as a result of obesity. B6 > BTBR.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Improving Glucose Metabolism With Resveratrol in.
Fatty Acid Metabolism 1. Fatty acid synthesis.
Control of Gene Expression Chapter 16 1 Biology Dual Enrollment Mrs. Mansfield.
Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Adrenergic-Fatty Acid Load in Heart Failure J.
Regulation of glucose levels in the blood is very important Normal Fasting (Serum) ~ 70 – 100 mg/dl Elevated = Diabetes Low = Hypoglycemia Insulin from.
Pyruvate Dehydrogenase Kinase 4: A potential drug target in non insulin dependent diabetes mellitus Thandeka Khoza.
Hormonal regulation of lipid metabolism
The effects of β-cell specific knockdown of FoxO1 during diet-induced obesity Oluwabukola A. Ajasa, Jennifer Fiori O’Connell, Michael Rouse, Adria Summers,
OXIDATION OF FATTY ACIDS
Micro-RNAs, Fatty Acids and Insulin Secretion
Volume 4, Issue 12, Pages (December 2015)
METABOLISM OF LIPIDS: SYNTHESIS OF FATTY ACIDS
BACE1 Knockout Mice and BACE1 inhibition in Mouse models of obesity/diabetes Stuart Irvine.
Nm23-H1 Regulates Glucose-Stimulated Insulin Secretion in Pancreatic β-Cells via Arf6-Rac1 Signaling Axis Cell Physiol Biochem 2013;32: DOI: /
Micro-RNA 132 and 212 mediated regulation of fatty acid metabolism and its effect on insulin secretion. Prelim Mock Talk by -Mufaddal S Soni Attie Lab.
MYC, Metabolism and Cancer
Normal And Abnormal Cardiac Muscle Metabolism
Volume 10, Issue 7, Pages (February 2015)
Volume 12, Issue 1, Pages (July 2010)
Won Hee Choi, Jiyun Ahn, Chang Hwa Jung, Jung Sook Seo, Tae Youl Ha 
Volume 13, Issue 1, Pages (October 2015)
Figure 21.1 Humans can use a variable fuel input to meet a variable metabolic demand. Textbook of Biochemistry with Clinical Correlations, 7e edited by.
Won Hee Choi, Jiyun Ahn, Chang Hwa Jung, Jung Sook Seo, Tae Youl Ha 
Pascal Ferré, Fabienne Foufelle  Cell Metabolism 
Volume 7, Issue 1, Pages (January 2008)
Review AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism CELL METABOLISM : JANUARY 2005 · VOL.
NASH: a mitochondrial disease
Volume 11, Issue 5, Pages (May 2010)
Volume 24, Issue 11, Pages (September 2018)
Volume 7, Issue 3, Pages (March 2001)
Is REDD1 a Metabolic Éminence Grise?
Volume 24, Issue 1, Pages e6 (July 2018)
Volume 22, Issue 3, Pages (March 2015)
Volume 19, Issue 4, Pages (April 2014)
Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk  Jennifer H. Stern, Joseph M. Rutkowski,
Autophagy: A Sweet Process in Diabetes
Volume 15, Issue 5, Pages (May 2012)
Cristoforo Silvestri, Vincenzo Di Marzo  Cell Metabolism 
mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
Role of adiponectin in human skeletal muscle bioenergetics
Maria Sara Remedi, Colin G. Nichols  Cell Metabolism 
Volume 9, Issue 5, Pages (May 2009)
Volume 20, Issue 4, Pages (October 2014)
AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism  Barbara B. Kahn, Thierry Alquier, David Carling,
Volume 6, Issue 1, Pages (July 2007)
Volume 7, Issue 5, Pages (June 2014)
Prevention of Steatosis by Hepatic JNK1
Volume 10, Issue 7, Pages (February 2015)
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Protein Tyrosine Phosphatase 1B
Lipid Metabolism Greases the Stem Cell Engine
18. Pancreatic function and metabolism
Volume 104, Issue 4, Pages (February 2001)
Lipid Sensing and Insulin Resistance in the Brain
Of Fat, β Cells, and Diabetes
Presentation transcript:

Micro-RNA 132 and 212 mediated regulation of fatty acid metabolism and its effect on insulin secretion. Prelim Mock Talk by -Mufaddal S Soni Attie Lab

Outline Introduction Preliminary Data Specific Aims: Conclusion Diabetes Micro-RNAs Preliminary Data Specific Aims: Determine the molecular fate of LC-Carn when stimulating insulin secretion. Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion. Conclusion The Economist, 12/13/03

Obesity-diabetes dichotomy Lean Obese B6 BTBR Obese Diabetic Age (weeks) 3

Micro-RNA 132 and 212 enhances insulin secretion.

Micro-RNA processing Transcription of pri-miRNA, Pri-miRNA processed by Drosha and DGCR8/Pasha, giving pre-miRNA, Pre-miRNA exported using exportin-5, Processed by dicer in the cytosol to give mature ds-miRNA. Ss-miRNA formed and incorporated into RISC. RISC degrades/translationally represses complementary RNA. Chang, Z. C. 2005

CACT (Slc25a20) : Most down regulated target of miRNA 132 and 212 Slc25a20 is the gene id for Cartnitine Acyl-Carnitine Translocase (CACT). Cells were profiled 10 and 24hrs after miRNA-132 and 212 overexpression. Red colored genes have seed region for the miRNAs.

CACT (Slc25a20) : Most down regulated target of miRNA 132 and 212 siCACT mimics the effect of miRNA on GSIS.

CACT mediates translocation of FA-Carn into the mitochondria for β-oxidation.

CACT mediates translocation of FA-Carn into the mitochondria for β-oxidation.

Fatty acyl carnitine enhances insulin secretion 50µM 10 mM Long chain carnitines are more sensitive towards enhancing insulin secretion.

Fatty acyl carnitine enhances insulin secretion 50µM 50µM 10 mM

Specific Aims Determine the molecular fate of LC-Carn when stimulating insulin secretion. Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion.

Specific Aims Determine the molecular fate of LC-Carn when stimulating insulin secretion. Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion.

Aim 1: Determine the molecular fate of LC-Carn when stimulating insulin secretion. Experiment 1: Decrease CPT-1 activity and determine if LC-Carn stimulates insulin secretion. Experiment 2: Determine if siRNA-mediated knockdown of CACT leads to reduced fatty acid β-oxidation. Experiment 3: Determine the molecular fate of exogenous FA-Carn under conditions when CACT activity is diminished. Experiment 4: Determine if a non-metabolized analog of fatty acyl-carnitine is capable of stimulating insulin secretion.

Aim 1: Determine the molecular fate of LC-Carn when stimulating insulin secretion. Experiment 1: Decrease CPT-1 activity and determine if LC-Carn stimulates insulin secretion. Experiment 2: Determine if siRNA-mediated knockdown of CACT leads to reduced fatty acid β-oxidation. Experiment 3: Determine the molecular fate of exogenous FA-Carn under conditions when CACT activity is diminished. Experiment 4: Determine if a non-metabolized analog of fatty acyl-carnitine is capable of stimulating insulin secretion.

Aim 1: Determine the molecular fate of LC-Carn when stimulating insulin secretion. Experiment 1: Decrease CPT-1 activity and determine if LC-Carn stimulates insulin secretion. Experiment 2: Determine if siRNA-mediated knockdown of CACT leads to reduced fatty acid β-oxidation. Experiment 3: Determine the molecular fate of exogenous FA-Carn under conditions when CACT activity is diminished. Experiment 4: Determine if a non-metabolized analog of fatty acyl-carnitine is capable of stimulating insulin secretion.

Aim 1: Determine the molecular fate of LC-Carn when stimulating insulin secretion. Experiment 1: Decrease CPT-1 activity and determine if LC-Carn stimulates insulin secretion. Experiment 2: Determine if siRNA-mediated knockdown of CACT leads to reduced fatty acid β-oxidation. Experiment 3: Determine the molecular fate of exogenous FA-Carn under conditions when CACT activity is diminished. Experiment 4: Determine if a non-metabolized analog of fatty acyl-carnitine is capable of stimulating insulin secretion.

Aim 1: Determine the molecular fate of LC-Carn when stimulating insulin secretion. Experiment 1: Decrease CPT-1 activity and determine if LC-Carn stimulates insulin secretion. Experiment 2: Determine if siRNA-mediated knockdown of CACT leads to reduced fatty acid β-oxidation. Experiment 3: Determine the molecular fate of exogenous FA-Carn under conditions when CACT activity is diminished. Experiment 4: Determine if a non-metabolized analog of fatty acyl-carnitine is capable of stimulating insulin secretion.

Aim 1: Determine the molecular fate of LC-Carn when stimulating insulin secretion. Experiment 1: Decrease CPT-1 activity and determine if LC-Carn stimulates insulin secretion. Experiment 2: Determine if siRNA-mediated knockdown of CACT leads to reduced fatty acid β-oxidation. Experiment 3: Determine the molecular fate of exogenous FA-Carn under conditions when CACT activity is diminished. Experiment 4: Determine if a non-metabolized analog of fatty acyl-carnitine is capable of stimulating insulin secretion.

Aim 1: Determine the molecular fate of LC-Carn when stimulating insulin secretion. Experiment 1: Decrease CPT-1 activity and determine if LC-Carn stimulates insulin secretion. Experiment 2: Determine if siRNA-mediated knockdown of CACT leads to reduced fatty acid β-oxidation. Experiment 3: Determine the molecular fate of exogenous FA-Carn under conditions when CACT activity is diminished. Experiment 4: Determine if a non-metabolized analog of fatty acyl-carnitine is capable of stimulating insulin secretion.

Specific Aims Determine the molecular fate of LC-Carn when stimulating insulin secretion. Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion.

Specific Aims Determine the molecular fate of LC-Carn when stimulating insulin secretion. Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion.

Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion.

Non-specific PKC inhibitor. Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn Ro 31-8220 Non-specific PKC inhibitor. LC-Carn

Conventional and novel PKC inhibitor. Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn PMA Conventional and novel PKC inhibitor. LC-Carn

Conventional PKC inhibitor. Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn UNC-01 Conventional PKC inhibitor. LC-Carn

Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn siRNAs against PKC isozymes responsible for LC-Carn mediated insulin secretion. LC-Carn

Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn LC-Carn

Measure increase in cAMP levels Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn Measure increase in cAMP levels LC-Carn

Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn H89 PKA inhibitor. LC-Carn

Inhibitor of Rap-GTP, an Epac effector. Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn Rap-GAP Inhibitor of Rap-GTP, an Epac effector. LC-Carn

Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn LC-Carn

Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. LC-Carn LC-Carn Wortmannin PI3K inhibitor LC-Carn

Aim 2: Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Experiment 1: Determine if LC-Carns enhance insulin secretion through PKC activation. Experiment 2: Study the role of cAMP and PKA in LC-Carn effects on insulin secretion. Experiment 3: Determine if the insulin signaling pathway is involved in LC-Carn mediated insulin secretion. Experiment 4: Identified proteins phosphorylated as a result of LC-Carn mediated PKC/PKA activation. Experiment 5: Determine the role of protein acylation in LC-Carn mediated insulin secretion. Phospho-proteomics if kinases are involved. What is Acylation? Acylation inhibition has been shown to blunt LC-CoA mediated insulin secretion. Inhibitors of Acylation: Cerulenin and 2-Br-palmitate.

Specific Aims Determine the molecular fate of LC-Carn when stimulating insulin secretion. Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion.

Specific Aims Determine the molecular fate of LC-Carn when stimulating insulin secretion. Identify the underlying signaling pathway for how LC-Carn enhances insulin secretion. Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion.

Aim 3: Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion. Prof. Randall Mynatt, LSU.

Glucose Tolerance Test (GTT) Aim 3: Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion. Experiment 1: Measure insulin secretion and glucose clearance of β-cell CrAT KO mice. Repeat GTT and also track insulin levels using C-peptide measurements. Perform ITT to measure insulin sensitivity of the CrAT KO mice Glucose Tolerance Test (GTT) Repeat the GSIS experiment on isolated islets from the CrAT KO mice with glucose and various other secretagogues. Prof. Randall Mynatt, LSU.

Insulin Tolerance Test (ITT) Aim 3: Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion. Experiment 1: Measure insulin secretion and glucose clearance of β-cell CrAT KO mice. Insulin Tolerance Test (ITT) Repeat GTT and also track insulin levels using C-peptide measurements. Perform ITT to measure insulin sensitivity of the CrAT KO mice Repeat the GSIS experiment on isolated islets from the CrAT KO mice with glucose and various other secretagogues

Glucose Stimulated Insulin Secretion (GSIS) Aim 3: Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion. Experiment 1: Measure insulin secretion and glucose clearance of β-cell CrAT KO mice. Repeat GTT and also track insulin levels using C-peptide measurements. Glucose Stimulated Insulin Secretion (GSIS) Perform ITT to measure insulin sensitivity of the CrAT KO mice Repeat the GSIS experiment on isolated islets from the CrAT KO mice with glucose and various other secretagogues. Prof. Randall Mynatt, LSU.

Amplification Pathway Aim 3: Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion. Experiment 2: Determine the phase of insulin secretion altered in CrAT mice. Amplification Pathway (2nd Phase) Triggering Pathway (1st Phase)

Experiment 3: Metabolic profiling of the βCrAT mouse islets. Aim 3: Elucidate the role of Carnitine Acetyl Transferase (CrAT) in regulating insulin secretion. Experiment 3: Metabolic profiling of the βCrAT mouse islets. Fat animals have elevated carnitine pools in the muscle. I will profile the carnitine metabolites in the βCrAT mouse islets to determine the correlation between insulin secretion and carnitine levels. Koves, R. T. et.al. 2007

Thank You Acknowledgements: Questions?

biotin–HPDP (Biotin-HPDP-N-[6-(Biotinamido)hexyl]-3′-(2′-pyridyldithio)propionamide